RNAI THERAPY FOR APBD AND LAFORA DISEASE
The present disclosure provides methods and compositions for the treatment of glycogen storage disorders, such as, for example, Lafora Disease and adult polyglucosan body disease. The methods and compositions of the present disclosure comprise isolated nucleic acid molecules, rAAV vectors and rAAV viral vectors comprising polynucleotide sequences encoding for artificial micro RNAs (amiRNAs) directed against GYS1.
1 . An rAAV vector comprising at least one polynucleotide sequence encoding at least one artificial micro RNA (amiRNA) directed against GYS1, wherein the at least one amiRNA directed against GYS1 comprises the nucleic acid sequence set forth in any one of SEQ ID NOs: 35-39.
2 . The rAAV vector of claim 1 , wherein the at least one polynucleotide comprises the nucleic acid sequences set forth in any one of SEQ ID NOS: 1-5.
3 . An rAAV vector of claim 1 or 2 , wherein the rAAV vector further comprises a first AAV ITR sequence.
4 . The rAAV vector of claim 3 , wherein the first AAV ITR sequence is an AAV2 ITR sequence.
5 . The rAAV vector of claim 3 or 4 , wherein the first AAV ITR sequence comprises the sequence set forth in SEQ ID NO: 14
6 . An rAAV vector of any one of claim 1-5 , wherein the rAAV vector further comprises a second AAV ITR sequence.
7 . The rAAV vector of claim 6 , wherein the second AAV ITR sequence is an AAV2 ITR sequence.
8 . The rAAV vector of claim 6 or 7 , wherein the second AAV ITR sequence comprises the sequence set forth in SEQ ID NO: 15
9 . The rAAV vector of any one of claims 1-8 , wherein the rAAV vector further comprises a promoter sequence.
10 . The rAAV vector of claim 9 , wherein the promoter sequence is a CBh promoter sequence.
11 . The rAAV vector of claim 10 , wherein the CBh promoter sequence comprises the nucleic acid sequence set forth in SEQ ID NO: 26.
12 . An rAAV vector comprising, in the 5′ to 3′ direction:
(a) a first AAV2 ITR sequence;
(b) a CBh promoter sequence;
(c) a polynucleotide sequence encoding for at least one amiRNA directed against GYS1 comprising the nucleic acid sequence of any one of SEQ ID NOs: 35-39; and
(d) a second AAV2 ITR sequence.
13 . The rAAV vector of claim 12 , wherein the rAAV vector comprises the sequence set forth in any one of SEQ ID NOs: 6-10.
14 . An rAAV viral vector comprising:
(a) an AAV capsid protein; and
(b) an rAAV vector of any one of claims 1 - 13 .
15 . The rAAV viral vector of claim 14 , wherein the AAV capsid protein is an AAV9 capsid protein.
16 . A pharmaceutical composition comprising the rAAV vector of any one of claims 1-13 or the rAAV viral vector of claim 14 or 15 ; and at least one pharmaceutically acceptable excipient and/or additive.
17 . A method for treating a subject having a glycogen storage disorder, the method comprising administering to the subject a therapeutically effective amount of the rAAV vector of any one of claims 1-13 , the rAAV viral vector of claim 14 or 15 , or the pharmaceutical composition of claim 16 .
18 . The method of claim 17 , wherein the rAAV vector, the rAAV viral vector, or the pharmaceutical composition is administered to the subject at a dose ranging from about 10 11 to about 10 18 viral vector particles.
19 . The method of claim 17 or 18 , wherein the rAAV vector, the rAAV viral vector, or pharmaceutical composition is administered intravenously or intrathecally.
20 . The method of any one of claims 17-19 , wherein the glycogen storage disorder is Lafora Disease or adult polyglucosan body disease.
21 . The rAAV vector of any one of claims 1-13 , the rAAV viral vector of claim 14 or 15 , or the pharmaceutical composition of claim 16 for use in the treatment of a glycogen storage disorder.
22 . The use of claim 21 , wherein the rAAV vector, the rAAV viral vector, or the pharmaceutical composition is for administration to a subject at a dose ranging from about 10 11 to about 10 18 viral vector particles.
23 . The use of claim 21 or 22 , wherein the rAAV vector, the rAAV viral vector, or pharmaceutical composition is for intravenous or intrathecal administration.
24 . The method of any one of claims 21-23 , wherein the glycogen storage disorder is Lafora Disease or adult polyglucosan body disease.